The New England journal of medicine
-
Comment Letter
Bivalent Boosters against Severe Omicron Infection. Reply.
-
Randomized Controlled Trial
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients with metastatic colorectal cancer. Preliminary data from single-group and randomized phase 2 trials suggest that treatment with FTD-TPI in addition to bevacizumab has the potential to extend survival. ⋯ Among patients with refractory metastatic colorectal cancer, treatment with FTD-TPI plus bevacizumab resulted in longer overall survival than FTD-TPI alone. (Funded by Servier and Taiho Oncology; SUNLIGHT ClinicalTrials.gov number, NCT04737187; EudraCT number, 2020-001976-14.).